JAK/TYK2

The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…

This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with…

The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. This study comparing the…

Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many…

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.Statins and major adverse cardiovascular…

The ACR Convergence meeting in Washington (#ACR24) will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use.…

It’s been eight years, and here we are again. The ACR annual meeting was last in Washington DC in 2016, and there’s probably a lot about ACR 2024 in DC that seems familiar. Maybe for some, it’s the…

This year at #ACR24, emulation trials are being presented.Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized…

ACR Convergence 2024 opened today with a full slate of presentations, posters and specialty meetings.  The meeting began with a flip: the plenary sessions started at 9AM and the poster session…

Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. Glucocorticoids were until relatively recently our sole…